Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
glutamic acid/inflamació
L'enllaç es desa al porta-retalls
15 resultats
Polysaccharidic esters of N-derivatives of glutamic acid
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to new products, namely polysaccharidic esters of N-derivatives of glutamic acid (N-GA). Their use as antiproliferatives in pharmaceutics is herein described.
PRIOR ART
Several modified polysaccharides have been described in the art. They are
Methods for treating joint pain using poly-gamma-glutamic acid
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates to methods for treating joint pain associated with inflammatory, degenerative and other joint diseases.
BACKGROUND OF THE INVENTION
Over 20 million people in the United States suffer from degenerative joint diseases. This results in over 2 million
Pharmaceutical composition for preventing or treating Th17-mediated disease comprising poly-gamma-glutamic acid
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCES TO RELATED APPLICATION
This patent application claims the benefit of priority from Korean Patent Application No. 2012-0037414, filed on Apr. 10, 2012 in the Korean Intellectual Property Office (KIPO), the entire contents of which are incorporated herein by reference.
BACKGROUND OF
Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This invention relates to amino acid derivatives, and more particularly to amino acid derivatives which possess anti-cholecystokinin activity. The invention also relates to methods for preparing such cholecystokinin antagonists and to compounds which are useful as intermediates in such
Hyaluronidase inhibitor containing poly-gamma-glutamic acid as an effective component
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/KR2005/003632 filed on 31 Oct. 2005 entitled "Hyaluronidase Inhibitor Containing Poly-Gamma-Glutamic Acid As An Effective
Method for synthesizing ramalin and ramalin precursor by using glutamic acid derivative and hydroxy aniline or hydroxy aniline having protected hydroxy group
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn.371 of International Patent Application No. PCT/KR12/02189 filed Mar. 26, 2012, which in turn claims priority of Korean Patent Application No. 10-2012-00069366 filed Jan. 19,
Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention concerns a new family of peptide molecules having the capacity especially of stimulating the expression of the cytokines of inflammation and promoting regeneration of tissues. The invention, thus, also pertains to pharmaceutical compositions containing at least
Muramyl compounds for treatment of septic shock
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This invention relates to the treatment and prophylaxis of sepsis, septic shock and other life-threatening inflammatory conditions.
The mortality of systemic bacterial infection (bacteraemia) is high, particularly for gram-negative infections, where mortality levels are still comparable to those of
Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The invention generally relates to treatments for abnormal cell proliferation, particularly for treating epidermal disorders, and more particularly relates to a method of inhibiting abnormal cell growth with the use of certain corticotropin-releasing hormone ("CRH") analogs.
Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The invention generally relates to treatments for abnormal cell proliferation, particularly for treating epidermal disorders, and more particularly relates to a method of inhibiting abnormal cell growth with the use of certain corticotropin-releasing hormone ("CRH") analogs.
Engineered botulinum neurotoxin
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Clostridium botulinum produces seven different neurotoxins (BoNTs) which differentiated serologically by the lack of anti-serum cross serotype neutralization. BoNTs are the most potent toxins known to humans and are the causative agents of the disease botulism (1). BoNTs
Orally administered small peptides synergize statin activity
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
This invention relates to the field of atherosclerosis. In particular, this invention pertains to the identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
BACKGROUND OF THE INVENTION
Cardiovascular
Method for preparing ramalin
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn.371 of International Patent Application No. PCT/KR11/05206 filed Jul. 14, 2011, which in turn claims priority of Korean Patent Application No. 10-2010-0067710 filed Jul. 14,
Amide derivatives of p-isobutyl-phenyl-propionic acids and related pharmaceutical compositions
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to amide derivatives of p-isobutyl-phenyl-propionic acid, having general formula: ##STR2## wherein X represents the radical of a substituted amine selected amongst lysine, metatrifluorotoluidine, glutamic acid and aspartic acid.
The anti-inflammatory properties of
Glycopeptide compositions
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to glycopeptide compositions containing a glycoside and a peptide and their uses as biomaterials. Specific embodiments relate to chitosan-based glycopeptides. More specific embodiments relate to glycopeptides including chitosan and poly(amino
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
